Arbutus Swings to $59.1 Million Profit on Patent Revenue

Arbutus Biopharma

WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported a $59.1 million third-quarter profit, reversing a $7.7 million loss a year earlier, as proceeds from its patent settlement with Moderna strengthened the Warminster biotechnology company’s finances and supported a $230 million return of capital to shareholders.

The company ended September 30, 2026, with $337.5 million in cash, cash equivalents and marketable securities, up from $91.5 million at the end of 2025. The balance included a $67.3 million dividend received from Genevant Sciences in connection with the Moderna settlement.

Arbutus earned $0.30 per basic and diluted share during the quarter, compared with a loss of $0.04 per share in the corresponding 2025 period.

The financial turnaround follows a March agreement with Moderna resolving worldwide patent infringement litigation involving lipid nanoparticle technology used to deliver messenger RNA vaccines.

Under the settlement, Moderna paid Arbutus and its exclusive licensee, Genevant, $950 million in July. Arbutus received $178.4 million as its share of that payment, including reimbursement of litigation expenses.

An additional $1.3 billion payment remains contingent on a federal appellate ruling concerning whether a provision of U.S. law limits patent infringement claims involving vaccines supplied to the federal government.

The U.S. Court of Appeals for the Federal Circuit heard expedited oral arguments November 5 concerning the application of 28 U.S.C. §1498. The outcome will determine whether the contingent settlement payment becomes payable under the agreement’s terms.

Arbutus also continues pursuing patent infringement claims against Pfizer and BioNTech involving lipid nanoparticle technology used in their COVID-19 vaccines.

The company and Genevant filed two additional lawsuits in Japan seeking damages and permanent injunctions against Pfizer Japan Inc. over alleged infringement of Japanese patents Nos. 5,475,753 and 7,936,499.

READ:  Hamilton Lane Profit Climbs as Private Market Assets Expand

In one Japanese case, Arbutus and Genevant submitted testing results from commercial Pfizer-BioNTech vaccine samples obtained in the United States and Europe. The companies contend the results demonstrate that the products contain lipid nanoparticles covered by their patent claims.

Arbutus and Genevant also amended an existing Canadian lawsuit against Pfizer, BioNTech and certain affiliates to include allegations involving newly issued Canadian Patent No. 2,767,127.

The additional proceedings expand litigation initiated in July, when the companies filed three international lawsuits seeking to enforce lipid nanoparticle patents across 21 countries.

Arbutus and Genevant are seeking monetary damages and injunctions against products they allege infringe the patents.

The patent proceeds have also reshaped Arbutus’ capital structure.

In early October, the company completed a modified Dutch auction tender offer, repurchasing 46 million common shares at $5 each for a total of $230 million.

The repurchase represented approximately 23% of the company’s outstanding common shares as of September 29. The acquired shares were canceled.

Arbutus had 199.3 million common shares outstanding at September 30, before completion of the tender offer, along with 6.4 million outstanding stock options and unvested restricted stock units.

For the first nine months of 2026, the company generated $225.7 million in net cash from operating activities and received another $19.3 million from stock option exercises.

Despite the quarterly profit, revenue from the company’s ongoing licensing activities declined.

READ:  Radian Doubles Revenue as Inigo Acquisition Drives Growth

Third-quarter revenue totaled $300,000, compared with $500,000 a year earlier, primarily reflecting lower royalties associated with declining sales of Alnylam Pharmaceuticals’ ONPATTRO.

Research and development expenses fell to $2.6 million from $5.8 million, reflecting workforce reductions, the discontinuation of internal scientific research and lower clinical trial expenses as studies approached completion.

General and administrative expenses increased to $8 million from $3 million, largely because of one-time cash bonuses paid to executives for their work related to the Moderna settlement.

Arbutus also reported a regulatory development affecting its remaining drug pipeline.

In October, the U.S. Food and Drug Administration lifted a clinical hold imposed in 2023 on the investigational new drug application for AB-101, an experimental oral PD-L1 inhibitor.

The decision allows Arbutus to pursue additional clinical development of AB-101 in the United States. The company is evaluating its next steps following a Phase 1 trial conducted outside the country.

AB-101 is designed to regulate immune checkpoint activity, potentially allowing immune cells to respond more effectively to hepatitis B virus while limiting some of the systemic safety concerns associated with checkpoint antibody therapies.

The company reported that AB-101 was generally well tolerated in its Phase 1a/1b study, with evidence of high receptor occupancy.

Arbutus is also continuing long-term follow-up of patients treated with imdusiran, its experimental RNA interference therapy for chronic hepatitis B.

The treatment is designed to reduce hepatitis B viral proteins and antigens, including hepatitis B surface antigen, potentially helping patients’ immune systems regain control of the infection.

In Phase 2a studies, eight patients achieved functional cure following treatment with imdusiran and nucleoside or nucleotide analogue therapy combined with either pegylated interferon alfa-2a or low-dose nivolumab plus an immunotherapeutic.

READ:  AdaptHealth Posts $168 Million Loss, Cuts Cash Flow Outlook

All eight remained virally suppressed and off nucleoside or nucleotide analogue therapy at the time of the company’s update, with five maintaining functional cure for more than two years.

Another 41 participants remained off that therapy for at least 48 weeks during their Phase 2a studies. Two additional patients achieved functional cure during long-term follow-up after discontinuing treatment.

Arbutus defines functional cure as sustained clearance of hepatitis B surface antigen and viral DNA below the quantification threshold after 24 weeks without treatment.

The company’s clinical research addresses a disease affecting more than 250 million people worldwide, according to World Health Organization estimates cited by Arbutus.

“We look forward to continuing this momentum in Q4 and beyond,” said Lindsay Androski, Arbutus’ president and chief executive officer, citing the shareholder tender offer and removal of the FDA clinical hold.

The company’s financial position now reflects a combination of substantial patent settlement proceeds, reduced research spending and continued litigation over lipid nanoparticle intellectual property.

Its near-term financial outlook remains tied in part to the pending Moderna appellate decision, while its remaining clinical programs advance following the FDA’s decision to permit renewed U.S. development of AB-101.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.